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Harold L. Atkins,1 Paolo A. Muraro,2 Jacob M. van Laar,3 Steven Z. Pavletic4Current systemic therapies are rarely curative for patients with severe life-threatening forms of autoimmune
disease (AID). During the past 15 years, autologous hematopoietic stem cell transplantation (HCT) has been
demonstrated to cure some patients with severe AID refractory to all other available therapies, and thus AID
has become an emerging indication for cell therapy. The sustained clinical effects after autologousHCTare bet-
ter explained by qualitative change in the reconstituted immune repertoire rather than transient depletion of
immune cells. Since 1996,more than 1300AID patients have been registered by the EuropeanGroup for Blood
andMarrowTransplantion (EBMT) and almost 500 patients by the Center for International Blood andMarrow
TransplantResearch (CIBMTR). AutologousHCT ismost commonly performed forpatientswithmultiple scle-
rosis (MS) or systemic sclerosis (SSc). Systemic lupus, Crohn’s disease, type I diabetes, and juvenile idiopathic
arthritis are other common indications. Allogeneic transplants are still considered too toxic for use in AID, ex-
cept for cases of immune cytopenia. Although biologic therapies have been effective at controlling the manifes-
tations of the disease, they require continuous administration, thus raising questions about their increasing
costs, morbidity, and mortality related to prolonged therapy. Perhaps it is a reasonable time to ask, ‘‘Is autol-
ogous HCT for severe AID now ready for prime time?’’ Yet, the paucity of controlled studies, the short-term
toxicities, and the upcoming availability of second-generation biologic and targeted immunotherapies argues
that perhaps HCT for AID should be still limited to clinical trials. In this article, we focus on the results of au-
tologousHCT forMS and SSc because these are the twomost commonly transplanted diseases. The promising
data that is emerging may establish these diseases as standard indications for HCT.
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Autoimmune diseases (AID) affect about 5% of
the population. Current systemic therapies are rarely
curative for those patients with the most severe, life-
threatening forms of AID. During the past 15 years,
based on the experience from experimental models
and early clinical trials, hematopoietic stem cell trans-
plantation (HCT) has become an emerging indication
for cell therapy. The use of HCT for AID has been
comprehensively reviewed [1]. Durable, progression-
free survival (PFS) in the range of approximately
50% is now reported for patients who have failed mul-
tiple therapies. Concurrently, there has been a signifi-
cant improvement in the safety of autologous HCT
[2]. The sustained clinical effects of autologous HCT
for AID are best explained by a qualitative changes in
the reconstituted immune repertoire rather than tran-
sient depletion of immune cells, supporting a hypothe-
sis that there is a ‘‘resetting’’ of the immune system [1].
Since 1996, more than 1300 AID patients have beenS177
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Marrow Transplantion (EBMT) and almost 500
patients by the Center for International Blood and
Marrow Transplant Research (CIBMTR) [3]. Autolo-
gous HCT is most commonly performed for patients
with multiple sclerosis (MS) or systemic sclerosis
(SSc). Systemic lupus, Crohn’s disease, type I diabetes,
and juvenile idiopathic arthritis are other common
indications. The majority of these HCT (90%) are
autologous procedures because allogeneic HCT is still
considered too toxic for use in AID, except for cases of
immune cytopenias.
Although biologic therapies have been effective at
controlling the manifestations of the disease, they
require continuous administration, thus raisingquestions
about their increasing costs, morbidity, andmortality re-
lated to prolonged therapy [4]. Thus, the prospect of de-
veloping a therapeutic option using a one-time
intervention with the potential of durable or curative
treatment-free survival is attractive. Given the alterna-
tives, perhaps it is a reasonable time to ask, ‘‘Is autologous
HCT for severe AID now ready for prime time?’’ Some
argue that given the paucity of controlled studies, the
short-term toxicities, and the upcoming availability of
second-generationbiologic and target immunotherapies,
HCT for AID should be limited to clinical trials. Here,
we focus solely on results of autologous HCT for MS
and SSc because these are the twomost commonly trans-
plantedAID.The promising data emerging from clinical
trials may turn the tide in the near future and establish
AID on the list of standard indications for HCT.AUTOLOGOUS HCT FOR MS
MS is an inflammatory demyelinating and degen-
erative disease of the central nervous system with
heterogeneous clinical features and a diverse long-
term prognosis. Relapsing-remitting (RR) MS is the
result of recurrent localized acute inflammation in
the central nervous system, whereas secondary pro-
gressive (SP) MS is an on-going neurodegenerative
state resulting from the accumulated damage caused
by the earlier recurrent inflammatory events and pos-
sibly compartmentalized CNS inflammation. Occa-
sionally, patients present with a progressive form of
MS (PP-MS) without a preceding RR phase. Inter-
feron-b and glatiramer acetate are most frequently
used as a first-line treatment for RRMS. Patients
who continue to experience relapses or begin to
develop progressive disabilities are often switched
to other agents such as natalizumab, fingolimod,
mitoxantrone, or cyclophosphamide. Several new
drugs for treating MS are in late-stage clinical trials
and may provide new alternatives for some patients
with RRMS. Mitoxantrone has been shown to tempo-
rarily halt or slow the tempo of progressive disabilities
during SPMS.Intensive immunosuppressive schemes have been
proposed as ‘‘salvage’’ therapy for some patients who
continue to deteriorate after these conventional treat-
ments. Pilot studies began in the 1990s and provided
the proof of principle that HCT could induce stabili-
zation in patients with severe MS. The HCT condi-
tioning regimen used for MS eliminates the existing
immune system that harbors disease-associated cells.
A new and healthy immune system regenerates from
immature hematopoietic progenitor cells [5]. Immu-
nologic studies have corroborated this notion by
linking the reduction of MS inflammatory events to
an extensive renewal of the adaptive immune system
following HCT, in which the T cell pool is gradually
repopulated by thymus-derived na€ıve cells [6].
Because of its risk profile, immunodepletion fol-
lowed by autologous HCT has been limited to patients
with highly active, rapidly deteriorating, treatment re-
fractory forms of MS. Registry data have documented
at least 400 patients have undergone autologous
HSCT for treatment of severe MS, either as part of
a clinical trial or under local protocols [7]. Heteroge-
neous patient populations and transplantation regi-
mens, a small number of patients, and lack of
a control arm reduce the quality of evidence that can
be inferred from these data. With this caveat in
mind, there is data available that provides support for
further exploration of the role of HCT in MS. Sup-
pression of relapses and of gadolinium-enhancing
MRI lesions after HSCT has been clearly demon-
strated [8-10]. Indeed, no other treatment has shown
such a degree of suppression of new MRI lesions in
the absence of any maintenance treatment [7]. How-
ever, because most trials of HCT inMS, until recently,
enrolled predominantly patients with progressive
forms (PP or SP), relapse rates are of limited usefulness
as an outcome measure for the evaluation of efficacy.
For this reason, as well as for its greater impact on pa-
tients’ quality of life, disability is considered a more
relevant outcome measure. The largest data set cur-
rently available is a retrospective analysis of data
from 178 patients reported to the EBMT Registry,
last updated in 2006 [11]. The analysis reported
a PFS in 60% to 70% of patients after 3 years and
50% to 60% after 6 to 8 years. More recent original re-
ports have shown a PFS that was disappointingly low
(36%) in a single study with 3-year follow-up, but
ranged from 70% to 100% after varying duration of
follow-up (1.5-6 years) in all other reports. Where ex-
tended follow-up of the patients was available, gradual
resumption of progression has been observed over
time [11-13].
The continued worsening of disability after HCT
has been associated with preexisting chronic, severe
disability (Expanded Disability Status Scale [EDSS]
6.0 and above) before HCT. More durable remissions
and, in some cases, improvement of neurologic
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ability (EDSS #6) and for patients in the RR phase
before HCT [14,15]. Burt et al. [16] recently treated
21 RRMS patients with mild to moderate disability
(EDSS 2.0-5.5) with a reduced-intensity conditioning
HCT regimen and reported 100% PFS, with 81%
showing an improvement of neurological function af-
ter a median of 3 years of follow-up. However, 25%
of patients experienced MS relapse following HCT,
which was higher than what was previously observed
in intermediate- and high-intensity regimes. Simi-
larly, Krasulova and colleagues [12] recently de-
scribed a case series treated in Prague and reported
a significantly higher rate of PFS in RR than in
SPMS patients. This report also confirmed an associ-
ation of better clinical outcomes in patients with short
disease duration (\5 years from diagnosis) and
a younger age, the latter in agreement with the
EBMT report and the experience from a Russian
case series [17]. Long-term follow-up data from
a larger number of patients is needed to document
and refine appropriate inclusion criteria and is the
purpose of a recently activated cooperative EBMT
and CIBMTR study.
Young patients with highly aggressive, rapidly
evolving (malignant) forms of MS constitute a group
that seems to especially benefit from HCT. These
forms have been termed ‘‘malignant’’ because of their
poor prognosis [18,19]. Case reports have described
dramatic clinical improvement, stabilization of lesion
burden, and suppression of relapses in patients with
highly active RRMS who had experienced high
numbers of relapses [20]. In a recent report by Fagius
and colleagues [18] on 9 patients treated with HCT
as rescue/salvage therapy for malignant RRMS, the
relapse rate dropped from61 in 82 patients/months be-
foreHCT to 1 in 289 patients/months followingHCT;
no enhancing lesionswere detected during follow-up in
two-thirds of the patients, andmost important, disabil-
ity was stabilized or improved in all patients with some
impressive functional recoveries [18].
Can this information be translated into practice?PATIENT SELECTION
The conditioning regimen is administered with
the goal of attenuating or abolishing the destructive
autoimmunity inMS patients. Thus, candidates for au-
tologous HCT should have evidence of inflammatory
activity (ongoing relapses or activity on magnetic res-
onance imaging [MRI]) to be considered for HCT. In-
deed, those patients with the most active MS, often
referred to as malignant MS, seem to have the clearest
benefit fromHCT. Patients with advanced disabilities,
especially those with PPMS or SPMS, who accumulate
disabilities without clear inflammatory activity are less
likely to benefit from HCT because the disabilitiesresult from a neurodegenerative process rather than
acute central nervous system inflammation. This is
particularly true of those patients with an EDSS score
of 6.5 or more. These patients require bilateral aids to
maintain mobility and are only able to walk for about
20 meters without rest and tend to have ongoing pro-
gression after HCT. HCT should be considered for
patients following careful selection in collaboration
with a neurologist who specializes in the care and treat-
ment of MS.
There is less data available to guide the selection of
patients with variants of MS, such as neuromyelitis op-
tica, for HCT. This variant is characterized by autoan-
tibodies against aquaporin 4, relapses manifesting as
optic neuritis and transverse myelitis, and the rapid de-
velopment of severe visual impairment and severe re-
strictions on mobility. HCT is being explored as
a novel treatment strategy given the severity of the
disabilities and the poor outcome with a standard
immune suppressive.PRETRANSPLANTATION EVALUATION
The patient should be thoroughly evaluated by an
MS specialist before HCT. The information that
should be in the transplant team’s documentation in-
clude: whether there is a familial or genetic predispo-
sition to MS; the frequency, severity, and
consequences of relapses; the patient’s prior drug ther-
apy; the current disabilities and their severity.
Furthermore, if a recent MRI is not available, it should
be performed before HCT to serve as a baseline for
future follow-up.
The Multiple Sclerosis Pre-HCT data form serves
as a useful tool to record MS specific information [21].
This form has been developed by a group of neurolo-
gists and transplant physicians familiar with HCT
for MS, and has been harmonized between the
EBMT Autoimmune Diseases Working Party and
the CIBMTR Autoimmune Diseases Working Com-
mittee. This core set of information provides a baseline
against which response to HCT can be judged.TREATMENT
The two most commonly used stem cell mobiliza-
tion regimens are granulocyte-colony stimulating fac-
tor (G-CSF) administered concurrently with steroids
and cyclophosphamide followed by G-CSF. G-CSF
may induce an MS relapse [15,22]; this can be
prevented by concurrent steroid or chemotherapy
administration.
Cyclophosphamide mobilized grafts have a lower
immune cell load that reduces the reintroduction
of autoreactive cells into the recipient during trans-
plantation. The Canadian MS study has used ex vivo
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deplete the graft products of immune cells to prevent
reintroduction of autoreactive cells.
Different centers have explored the use of condi-
tioning regimens with varying immune andmyeloabla-
tive intensity. A common low-intensity regimen is
composed of cyclophosphamide given in combination
with a lymphocyte depleting antibody such as antithy-
mocyte globulin (ATG) [16]. More intensive regimens
include BEAM with ATG [11] or busulfan with cyclo-
phosphamide and ATG [23]. Although a low-intensity
regimen may reduce complications, higher-intensity
regimens may offer better long-term control of MS.MORTALITY
The high risk of serious adverse events, including
death, tempered the development of HCT as treat-
ment for MS. However, there are clear signals that
risks related to HCT can be reduced. In a recent
analysis of all the European cases registered in the
EBMT database (n 5 338), treatment-related mortal-
ity (TRM) was 3.3% [7]. However, TRM decreased
from 7.3% in 1995 to 2000 to 1.3% in 2001 to 2007.
The data suggests that increased experience including
more appropriate patient selection has led to improved
safety. MS itself does not appear to increase the risk of
HCT-related mortality.OTHER COMPLICATIONS DURING
MOBILIZATION, COLLECTION, AND
TRANSPLANTATION
MS patients considered for HCT tend to be young
to middle-age adults with few comorbidities. MS
patients undergoing HCT experience the expected
complications at roughly the same frequency as
patients undergoing autologous HCT for lymphoma.
Intensive conditioning regimens and graft lymphocyte
depletion may present greater risk of toxicities and in-
fectious complications [24]. Low-intensity treatments
with minimal myelosuppressive effects have been
proposed in order to reduce the toxicity of the condi-
tioning regimen [16], but may be less effective.
A few complications occur more frequently or are
unique to the MS transplant recipients. Urinary tract
infections are common because of the regularity
of bladder dysfunction in the MS population and a
frequent need for bladder catheterization, for instance,
to prevent hemorrhagic cystitis during cyclophospha-
mide administration. Febrile neutropenia and infec-
tions may precipitate a pseudorelapse, causing
transient worsening of the MS symptoms and disabil-
ities. Awareness may minimize extraneous tests, avoid
inadvertent pulse steroid treatment, and allow the
transplant team to reassure the patient. MS patients,usually those with a greater degree of disability before
transplantation, are at risk of developing further loss
of mobility because of the chemotherapy-induced
cachexia and myopathy. Access to physiotherapy
during theHCT admissionmaymitigate this problem,
although some patients require transfer to a specialized
rehabilitation unit to foster the recovery from the
worsened disabilities. Recipients of CD34 selected
grafts treated with ATG are at risk for a spectrum
of herpes virus reactivations including shingles,
Epstein-Barr virus lymphoproliferation [25], HHV-
6, and cytomegalovirus viremia. Active surveillance
and/or antiviral prophylaxis are warranted.
Autoimmune phenomena not related to MS may
occur in the late posttransplantation period. These
may be related to the use of lymphocyte depleting
antibodies given in the conditioning regimen. Auto-
immune thyroid disease has been seen in almost
20% of the patients at our center. Autoimmune cyto-
penias, predominantly idiopathic thrombocytopenic
purpura, may also occur up to several years posttrans-
plantation [26].POSTTRANSPLANTATION EVALUATIONS
The patient should be thoroughly evaluated every
6 to 12 months following HCT by an MS specialist to
monitor for any evidence of relapses, deterioration
in preexisting disabilities, or the development of new
disabilities. An annual MRI is considered warranted
in the longitudinal follow-up of the patient. The
Multiple Sclerosis Post-HSCT data form serves as a
useful tool to record thisMS-specific information [21].ONGOING AND FUTURE TRIALS
At present, it remains unclear which conditioning
regimen offers the optimal risk/benefit ratio. A study
of nonmyeloablative HCT (ClinicalTrials.gov Identi-
fier: NCT00273364) versus approved standard of care
(ie, interferon, copaxone, or mitoxantrone) is currently
active and open to recruitment at Northwestern Uni-
versity, Chicago, IL. Three trials have recently been
completed or closed for recruitment, and the results
are pending: (1) the Canadian MSBMT trial, using
a conditioning regimen of busulphan, cyclophospha-
mide, and ATG conditioning regimen; (2) the random-
ized phase II Autologous Stem cell Transplantation
International Multiple Sclerosis Trial in which the
transplantation arm consisted of BEAM-ATG using
an unmanipulated autologous stem cell graft collected
after mobilization with cyclophosphamide compared
with a control arm receivingmitoxantrone (www.astim-
s.org); (3) themulticenterU.S. Phase 2TrialHigh-dose
Immunosuppression and Autologous Transplantation
for Multiple Sclerosis (ClinicalTrials.gov Identifier:
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followed by transplantation of a CD34-selected stem
cell graft collected using G-CSF and steroids.
European and North American investigators are
currently developing a larger multicenter randomized
controlled phase 3 trial. This trial will assess the safety
and efficacy of autologous HSCT versus standard of
care in highly active, treatment-refractory RRMS.
The details of inclusion criteria, treatment regimen,
and outcomemeasures have been summarised in a con-
sensus report (Saccardi et al., submitted). This con-
trolled trial will likely finally provide the evidence
required to establish the role of HCT for treatment
of severe, active forms of MS.AUTOLOGOUS HCT FOR SSC
SSc is a rare, heterogeneous disease with a spec-
trum of clinical manifestations with vasculopathy,
inflammation, fibrosis, and laboratory features of
autoimmunity. SSc is commonly divided in 2 subsets:
limited cutaneous SSc and diffuse cutaneous (dc)
SSc. The former is generally accepted to be more
benign in its clinical features, disease course, and prog-
nosis, whereas the latter can be a life-threatening con-
dition. Most transplant physicians and hematologists
will not routinely be involved in the care of SSc pa-
tients because this rare connective tissue disease does
not normally present with hematologic manifestations
other than anemia of chronic disease or instances of
thrombotic thrombocytopenic purpura associated
with renal crisis. This may change if and when HCT
becomes an accepted treatment option for selected
patients suffering from severe SSc.
SSc is feared among rheumatologists and patients,
for it is the most devastating connective tissue disease.
Overall survival of SSc patients has improved in the
past decade, because of intensive management with
the use of ACE inhibitors to prevent ‘‘scleroderma
renal crisis’’ and immunosuppressive medication for
joint involvement and interstitial lung disease. Atten-
tion to nutritional measures, smoking cessation, and
lifestyle interventions (exercise therapy and physio-
therapy aimed at preservation of functional ability)
may also contribute to a better outlook. Despite this,
a proportion of patients with dcSSc have relentless
disease progression with extensive skin involvement
and visceral organ dysfunction.
Given the paucity of proven disease-modifying
treatments in SSc, it is not surprising that SSc was
one of the first autoimmune diseases targeted with
HCT. Although some early case reports showed ben-
eficial effects of autologous HCT on some disease-
specific manifestations such as skin thickening, others
uncovered the risks of HCT for patients with SSc.
Data from registry analyses and several phase 1/2 trials
confirmed that HCT is a powerful treatment modalityfor SSc but with significant risks for a patient [27-30].
In the early days, TRM of HCT ranged from 8%
to 23%, illustrating the challenges facing HCT in
SSc. There is a perception among specialists in the
field that some nonfatal serious adverse events such
as heart failure and respiratory distress syndrome
occur more commonly in SSc patients who have
undergone HCT. So what makes SSc patients more
vulnerable to HCT-related toxicity? As the name
systemic sclerosis implies, SSc is characterized by
generalized matrix deposition, most prominently
in skin (which explains its alternative name
‘‘scleroderma’’), but also in visceral organs (heart,
lung, kidneys, gut). Heart involvement is often
subclinical and may go undetected by ECG and
routine cardiac echocardiography. Small vessel
disease, a hallmark of SSc, may contribute to silent
cardiac ischemia and patchy fibrosis leading to
ventricular arrhythmia. Cardiac fibrosis can be
quantified with MRI, but its utility in identifying
high-risk patients remains to be demonstrated. Pulmo-
nary arterial hypertension is a risk factor for right
ventricular diastolic dysfunction, explaining why SSc
patients do not always tolerate hyperhydration.
Prophylactic implantation of a pacemaker or implant-
able cardioverter-defibrillator should be considered in
selected SSc patients. Other toxicities result from lung
involvement, which predisposes to respiratory insuffi-
ciency from a cytokine release syndrome associated
with administration of ATG or total body irridiation,
and gut involvement requiring parenteral nutrition
with its attendant risks.
One might conclude that the risks of HCT in SSc
are unacceptable. However, such a pessimistic inter-
pretation of the available data may be premature.
With growing experience, TRM has been dramatically
reduced. This may be because of better patient selec-
tion, screening, monitoring, and follow-up [2]. These
factors may also partially explain the excellent results
from a recent single-center controlled, open-label,
randomized phase 2 trial of 19 patients. HCT patients
received cyclophosphamide 2 g/m2 1 G-CSF for
mobilization, cyclophosphamide 200 mg/kg 1 rabbit
ATG 6.5 mg/kg for conditioning, followed by reinfu-
sion of unmanipulated autologous HCT. There were
statistically significant improvements of the modified
Rodnan skin score (a validated measure of extent of
skin thickening), lung function (forced vital capacity
but not diffusing capacity of carbon monoxide), and
quality of life as measured by SF-36 at 12 months for
patients who underwent HCT [30]. Most control
patients who crossed over to the HCT arm because
of disease progression also showed benefits from
HCT. Remarkably, no deaths occurred in either
arm. The study was not designed to demonstrate a sur-
vival benefit, and follow-up was too limited to assess
late effects.
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come clear from two on-going prospective, random-
ized, controlled phase 3 studies, the ASTIS trial and
the SCOT trial, which were launched in the past de-
cade to compare safety and long-term efficacy of
HCT versus cyclophosphamde i.v. pulse therapy for
patients with early dcSSc. The ASTIS trial in Europe
compares autologous HCT (mobilization with cyclo-
phosphamide 2  2 g/m2, G-CSF, conditioning with
cyclophosphamide 200 mg/kg 1 rabbit ATG 7.5
mg/kg, followed by reinfusion of CD341 selected au-
tologous HCT) versus 12 monthly cycles of i.v. pulse
cyclophosphamide 750 mg/m2. With 156 patients en-
rolled and a median follow-up of 5 years, the first out-
come data will become available in 2012. The North
American SCOT trial compares mobilization with
G-CSF, conditioning with cyclophosphamide 120
mg/kg, horse ATG 90 mg/kg, total body irridiation
8 Gy with lung and kidney shielding, followed by rein-
fusion of CD341 selected HCT with a control arm
that is almost identical to the one in the ASTIS trial.
The patient eligibility criteria and outcome parame-
ters of SCOT and ASTIS are broadly similar to allow
future comparative analyses of outcome data. The re-
sults of the ASTIS and SCOT trial will yield important
data on overall survival, event-free survival, disease-
free survival, serious adverse events, and long-term
toxicity ofHCTversus standard chemotherapy in a rel-
atively high number of patients with early dcSSc.
These trials will also help determine whether the ben-
efits ofHCToutweigh the risks based on a broad range
of additional secondary outcome measures. As such,
these are the first large, randomized HCT trials in
the field of autoimmune disease. A positive outcome
may therefore give an impetus to further studies in
other severe autoimmune diseases that are refractory
to conventional therapy.ACKNOWLEDGMENTS
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